Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring

Launched by THE INSTITUTE OF MOLECULAR AND TRANSLATIONAL MEDICINE, CZECH REPUBLIC · Mar 7, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to monitor treatment for certain cancers linked to the human papillomavirus (HPV), such as cervical cancer and oropharyngeal cancer. The researchers want to see if a test called a liquid biopsy, which analyzes a sample of blood or other body fluids, can help find signs of cancer returning earlier than current methods. By finding the right combination of tests and markers, the goal is to better understand which patients are at higher risk of their cancer coming back.

If you are a woman diagnosed with cervical cancer or high-grade cervical lesions, or a man or woman diagnosed with oropharyngeal cancer, you may be eligible to participate in this study. There are no specific exclusion criteria, so many patients may qualify. Participants will need to agree to join the study and sign an informed consent form. Throughout the trial, you'll be closely monitored, and your involvement will help researchers learn more about how to improve cancer treatment and monitoring for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Women diagnosed with CC/HSIL. Men and women diagnosed with OPC. Patients must agree with study enrollment and must sign study informed consent.
• Exclusion Criteria:
• • No exclusion criteria are set.